{"id":"cabergoline","rwe":[{"pmid":"41891968","year":"2026","title":"circOMA1 delivered by exosomes regulates DRD2‑mediated prolactinoma resistance.","finding":"","journal":"International journal of molecular medicine","studyType":"Clinical Study"},{"pmid":"41884493","year":"2026","title":"Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities.","finding":"","journal":"JFMS open reports","studyType":"Clinical Study"},{"pmid":"41879940","year":"2026","title":"Pregnancy and delivery after surgical remission in women with prolactinomas desiring pregnancy: Refining surgical indications.","finding":"","journal":"Pituitary","studyType":"Clinical Study"},{"pmid":"41866242","year":"2026","title":"Aortic dissection during the perinatal period in women with Marfan-related disorders: a retrospective cohort study using the Japanese Diagnosis Procedure Combination database.","finding":"","journal":"The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians","studyType":"Clinical Study"},{"pmid":"41827470","year":"2026","title":"Cabergoline Therapy and Tumor Growth Rate in Pituitary Microadenomas: A Retrospective Cohort Study.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"}],"_fda":{"id":"45723c3c-bc96-6df6-e063-6294a90a8e1f","set_id":"275a6a25-c3c9-4258-a610-0b00752517f7","openfda":{"nui":["M0007652","N0000175827"],"upc":["0370512860080"],"unii":["LL60K9J05T"],"route":["ORAL"],"rxcui":["199703"],"spl_id":["45723c3c-bc96-6df6-e063-6294a90a8e1f"],"brand_name":["Cabergoline"],"spl_set_id":["275a6a25-c3c9-4258-a610-0b00752517f7"],"package_ndc":["70512-860-08"],"product_ndc":["70512-860"],"generic_name":["CABERGOLINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Ergolines [CS]"],"substance_name":["CABERGOLINE"],"pharm_class_epc":["Ergot Derivative [EPC]"],"manufacturer_name":["SOLA Pharmaceuticals, LLC"],"application_number":["ANDA076310"],"is_original_packager":[true]},"version":"4","warnings":["WARNINGS 1. Pregnancy: Dopamine agonists in general should not be used in patients with pregnancy-induced hypertension, for example, preeclampsia, eclampsia, and postpartum hypertension, unless the potential benefit is judged to outweigh the possible risk. 2. Fibrotic Complications: a. Cardiac Valvulopathy: All patients should undergo a cardiovascular evaluation, including echocardiogram to assess the potential presence of valvular disease. If valvular disease is detected, the patient should not be treated with Cabergoline (See CONTRAINDICATIONS ) . Post-marketing cases of cardiac valvulopathy have been reported in patients receiving Cabergoline. These cases have generally occurred during administration of high doses of Cabergoline (>2mg/day) used for the treatment of Parkinson’s disease. Cases of cardiac valvulopathy have also been reported in patients receiving lower doses for the treatment of hyperprolactinemic disorders. A multi-country, retrospective cohort study using general practice records and record linkage systems in the UK, Italy and the Netherlands was conducted to assess the association between new use of dopamine agonists including cabergoline (n=27,812) for Parkinson’s disease and hyperprolactinemia and cardiac valvular regurgitation (CVR), other fibroses, and other cardiopulmonary events over a maximum of 12 years of follow up. In this study, the use of cabergoline among persons with Parkinson’s disease was associated with an increased risk of CVR when compared to non-ergot-derived dopamine agonists (Das) and levodopa [Incidence Rate (IR) per 10,000 person years of 68.1 (95% confidence interval (CI): 37.2 to 115.3) for cabergoline vs. 10.0 (95% CI: 5.2 to 19.4) for non-ergot Das and 11.3 (95% CI: 7.2 to 17.0) for levodopa]. In the study analysis confined to persons with dopamine agonist-treated hyperprolactinemia (n=8,386), when compared to non-use (n=15,147), persons exposed to cabergoline did not have an elevated risk of CVR. The findings with respect to the risk of CVR associated with cabergoline treatment for persons with Parkinson’s disease (increased risk) and those with hyperprolactinemia (no increased risk) are consistent with the findings in other published studies. Physicians should use the lowest effective dose of Cabergoline for the treatment of hyperprolactinemic disorders and should periodically reassess the need for continuing therapy with Cabergoline. Following treatment initiation, clinical and diagnostic monitoring (for example, chest x-ray, CT scan and cardiac echocardiogram) should be conducted to assess the risk of cardiac valvulopathy. The recommended frequency of routine echocardiographic monitoring is every 6 to 12 months or as clinically indicated with the presence of signs and symptoms such as edema, new cardiac murmer, dyspnea or congestive heart failure. Cabergoline should be discontinued if an echocardiogram reveals new valvular regurgitation, valvular restriction or valve leaflet thickening. Cabergoline should be used with caution in patients exposed to other medications associated with valvulopathy. b. Extracardiac Fibrotic Reactions: Post-marketing cases of pleural, pericardial and retroperitoneal fibrosis have been following administration of Cabergoline. Some reports were in patients previously treated with other ergotinic dopamine agonists. Cabergoline should not be used in patients with a history of cardiac or extracardiac fibrotic disorders. Fibrotic disorders can have an insidious onset and patients should be monitored for manifestations of progressive fibrosis. Therefore, during treatment, attention should be paid to the signs and symptoms of: Pleuro-pulmonary disease such as dyspnea, shortness of breath, persistent cough or chest pain. Renal insufficiency or ureteral/abdominal vascular obstruction that may occur with pain in the loin/flank and lower limb edema as well as any possible abdominal masses or tenderness that may indicate retroperitoneal fibrosis. Cardiac failure: Cases of valvular and pericardial fibrosis have ofter manifested as cardiac failure. Therefore, valvular fibrosis (and constrictive pericarditis) should be excluded if such symptoms occur. Clinical and diagnostic monitoring such as erythrocyte sedimentation rate, chest x-ray, serum creatinine measurements, and other investigations should be considered at baseline and as necessary while patients are treated with Cabergoline. Following diagnosis of pleural effusion or pulmonary fibrosis, the discontinuance of Cabergoline was reported to result in improvement of signs and symptoms."],"pregnancy":["Pregnancy: Teratogenic Effects: Category B. Reproduction studies have been performed with cabergoline in mice, rats, and rabbits administered by gavage. (Multiples of the maximum recommended human dose in this section are calculated on a body surface area basis using total mg/m 2 /week for animals and mg/m 2 /week for a 50 kg human.) There were maternotoxic effects but no teratogenic effects in mice given cabergoline at doses up to 8 mg/kg/day (approximately 55 times the maximum recommended human dose) during the period of organogenesis. A dose of 0.012 mg/kg/day (approximately 1/7 the maximum recommended human dose) during the period of organogenesis in rats caused an increase in post-implantation embryofetal losses. These losses could be due to the prolactin inhibitory properties of cabergoline in rats. At daily doses of 0.5 mg/kg/day (approximately 19 times the maximum recommended human dose) during the period of organogenesis in the rabbit, cabergoline caused maternotoxicity characterized by a loss of body weight and decreased food consumption. Doses of 4 mg/kg/day (approximately 150 times the maximum recommended human dose) during the period of organogenesis in the rabbit caused an increased occurrence of various malformations. However, in another study in rabbits, no treatment-related malformations or embryofetotoxicity were observed at doses up to 8 mg/kg/day (approximately 300 times the maximum human dose). In rats, doses higher than 0.003 mg/kg/day (approximately 1/28 the maximum recommended human dose) from 6 days before parturition and throughout the lactation period inhibited growth and caused death of offspring due to decreased milk secretion. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."],"overdosage":["OVERDOSAGE Overdosage might be expected to produce nasal congestion, syncope, or hallucinations. Measures to support blood pressure should be taken if necessary."],"description":["DESCRIPTION Cabergoline Tablets, USP contain cabergoline USP, a dopamine receptor agonist. The chemical name for cabergoline USP is 1-[(6-allylergolin-8ß-yl)-carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea. Its molecular formula is C 26 H 37 N 5 O 2 , and its molecular weight is 451.62. The structural formula is as follows: Cabergoline USP is a white powder soluble in ethyl alcohol, chloroform, and N, N-dimethylformamide (DMF); slightly soluble in 0.1N hydrochloric acid; very slightly soluble in n-hexane; and insoluble in water. Each tablet, for oral administration, contains 0.5 mg of cabergoline USP. Inactive ingredients consist of citric acid, croscarmellose sodium, magnesium stearate and microcrystalline cellulose. Chemical Structure"],"precautions":["PRECAUTIONS General: Initial doses higher than 1.0 mg may produce orthostatic hypotension. Care should be exercised when administering cabergoline with other medications known to lower blood pressure. Postpartum Lactation Inhibition or Suppression: Cabergoline is not indicated for the inhibition or suppression of physiologic lactation. Use of bromocriptine, another dopamine agonist for this purpose, has been associated with cases of hypertension, stroke, and seizures. Hepatic Impairment: Since cabergoline is extensively metabolized by the liver, caution should be used, and careful monitoring exercised, when administering cabergoline to patients with hepatic impairment. Psychiatric: Impulse control/compulsive behaviors, including pathological gambling, increased libido, and hypersexuality, have been reported in patients treated with dopamine agonists including cabergoline. This has been generally reversible upon reduction of the dose or treatment discontinuation (see Post-marketing Surveillance data ). Prescribers should consider dose reduction or stopping the medication if a patient develops such urges while taking cabergoline. Information for Patients: Patients should be instructed to notify their physician if they suspect they are pregnant, become pregnant, or intend to become pregnant during therapy. A pregnancy test should be done if there is any suspicion of pregnancy and continuation of treatment should be discussed with their physician. Patients should notify their physician if they develop shortness of breath, persistent cough, difficulty with breathing when lying down, or swelling in their extremities. Patients should be alerted to the possibility that patients may experience intense urges to spend money uncontrollably, intense urges to gamble, increased sexual urges, and other intense urges and the inability to control these urges while taking cabergoline. Advise patients to inform their healthcare provider if they develop new or increased uncontrolled spending, gambling urges, sexual urges, or other urges while being treated with cabergoline (see PRECAUTIONS ). Drug Interactions: Cabergoline should not be administered concurrently with D 2 -antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide. Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenicity studies were conducted in mice and rats with cabergoline given by gavage at doses up to 0.98 mg/kg/day and 0.32 mg/kg/day, respectively. These doses are 7 times and 4 times the maximum recommended human dose calculated on a body surface area basis using total mg/m 2 /week in rodents and mg/m 2 /week for a 50 kg human. There was a slight increase in the incidence of cervical and uterine leiomyomas and uterine leiomyosarcomas in mice. In rats, there was a slight increase in malignant tumors of the cervix and uterus and interstitial cell adenomas. The occurrence of tumors in female rodents may be related to the prolonged suppression of prolactin secretion because prolactin is needed in rodents for the maintenance of the corpus luteum. In the absence of prolactin, the estrogen/progesterone ratio is increased, thereby increasing the risk for uterine tumors. In male rodents, the decrease in serum prolactin levels was associated with an increase in serum luteinizing hormone, which is thought to be a compensatory effect to maintain testicular steroid synthesis. Since these hormonal mechanisms are thought to be species-specific, the relevance of these tumors to humans is not known. The mutagenic potential of cabergoline was evaluated and found to be negative in a battery of in vitro tests. These tests included the bacterial mutation (Ames) test with Salmonella typhimurium , the gene mutation assay with Schizosaccharomyces pombe P1 and V79 Chinese hamster cells, DNA damage and repair in Saccharomyces cerevisiae D4 , and chromosomal aberrations in human lymphocytes. Cabergoline was also negative in the bone marrow micronucleus test in the mouse. In female rats, a daily dose of 0.003 mg/kg for 2 weeks prior to mating and throughout the mating period inhibited conception. This dose represents approximately 1/28 the maximum recommended human dose calculated on a body surface area basis using total mg/m 2 /week in rats and mg/m 2 /week for a 50 kg human. Pregnancy: Teratogenic Effects: Category B. Reproduction studies have been performed with cabergoline in mice, rats, and rabbits administered by gavage. (Multiples of the maximum recommended human dose in this section are calculated on a body surface area basis using total mg/m 2 /week for animals and mg/m 2 /week for a 50 kg human.) There were maternotoxic effects but no teratogenic effects in mice given cabergoline at doses up to 8 mg/kg/day (approximately 55 times the maximum recommended human dose) during the period of organogenesis. A dose of 0.012 mg/kg/day (approximately 1/7 the maximum recommended human dose) during the period of organogenesis in rats caused an increase in post-implantation embryofetal losses. These losses could be due to the prolactin inhibitory properties of cabergoline in rats. At daily doses of 0.5 mg/kg/day (approximately 19 times the maximum recommended human dose) during the period of organogenesis in the rabbit, cabergoline caused maternotoxicity characterized by a loss of body weight and decreased food consumption. Doses of 4 mg/kg/day (approximately 150 times the maximum recommended human dose) during the period of organogenesis in the rabbit caused an increased occurrence of various malformations. However, in another study in rabbits, no treatment-related malformations or embryofetotoxicity were observed at doses up to 8 mg/kg/day (approximately 300 times the maximum human dose). In rats, doses higher than 0.003 mg/kg/day (approximately 1/28 the maximum recommended human dose) from 6 days before parturition and throughout the lactation period inhibited growth and caused death of offspring due to decreased milk secretion. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from cabergoline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Use of cabergoline for the inhibition or suppression of physiologic lactation is not recommended (see PRECAUTIONS section). The prolactin-lowering action of cabergoline suggests that it will interfere with lactation. Due to this interference with lactation, cabergoline should not be given to women postpartum who are breastfeeding or who are planning to breastfeed. Pediatric Use: Safety and effectiveness of cabergoline in pediatric patients have not been established. Geriatric Use: Clinical studies of cabergoline did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"how_supplied":["HOW SUPPLIED Cabergoline Tablets, USP are a white to off-white, oval shape, flat face, beveled edge tablet containing 0.5 mg cabergoline USP. Each tablet is debossed “P” bisect line “P” on one side and “673\" on the other side. Cabergoline Tablets, USP are available as follows: Bottles of 8 tablets NDC 70512-860-08"],"geriatric_use":["Geriatric Use: Clinical studies of cabergoline did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["Pediatric Use: Safety and effectiveness of cabergoline in pediatric patients have not been established."],"effective_time":"20251208","nursing_mothers":["Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from cabergoline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Use of cabergoline for the inhibition or suppression of physiologic lactation is not recommended (see PRECAUTIONS section). The prolactin-lowering action of cabergoline suggests that it will interfere with lactation. Due to this interference with lactation, cabergoline should not be given to women postpartum who are breastfeeding or who are planning to breastfeed."],"clinical_studies":["Clinical Studies: The prolactin-lowering efficacy of cabergoline was demonstrated in hyperprolactinemic women in two randomized, double-blind, comparative studies, one with placebo and the other with bromocriptine. In the placebo-controlled study (placebo n=20; cabergoline n=168), cabergoline produced a dose-related decrease in serum prolactin levels with prolactin normalized after 4 weeks of treatment in 29%, 76%, 74% and 95% of the patients receiving 0.125, 0.5, 0.75, and 1 mg twice weekly, respectively. In the 8-week, double-blind period of the comparative trial with bromocriptine (cabergoline n=223; bromocriptine n=236 in the intent-to-treat analysis), prolactin was normalized in 77% of the patients treated with cabergoline at 0.5 mg twice weekly compared with 59% of those treated with bromocriptine at 2.5 mg twice daily. Restoration of menses occurred in 77% of the women treated with cabergoline, compared with 70% of those treated with bromocriptine. Among patients with galactorrhea, this symptom disappeared in 73% of those treated with cabergoline compared with 56% of those treated with bromocriptine."],"adverse_reactions":["ADVERSE REACTIONS The safety of Cabergoline Tablets has been evaluated in more than 900 patients with hyperprolactinemic disorders. Most adverse events were mild or moderate in severity. In a 4-week, double-blind, placebo-controlled study, treatment consisted of placebo or cabergoline at fixed doses of 0.125, 0.5, 0.75, or 1 mg twice weekly. Doses were halved during the first week. Since a possible dose-related effect was observed for nausea only, the four cabergoline treatment groups have been combined. The incidence of the most common adverse events during the placebo-controlled study is presented in the following table. Incidence of Reported Adverse Events During the 4-Week, Double-Blind, Placebo-Controlled Trial Adverse Event Reported at ≥1% for cabergoline Cabergoline (n=168) 0.125 to 1 mg two times a week Placebo (n=20) Number (percent) Gastrointestinal Nausea 45 (27) 4 (20) Constipation 16 (10) 0 Abdominal pain 9 (5) 1 (5) Dyspepsia 4 (2) 0 Vomiting 4 (2) 0 Central and Peripheral Nervous System Headache 43 (26) 5 (25) Dizziness 25 (15) 1 (5) Paresthesia 2 (1) 0 Vertigo 2 (1) 0 Body As a Whole Asthenia 15 (9) 2 (10) Fatigue 12 (7) 0 Hot flashes 2 (1) 1 (5) Psychiatric Somnolence 9 (5) 1 (5) Depression 5 (3) 1 (5) Nervousness 4 (2) 0 Autonomic Nervous System Postural hypotension 6 (4) 0 Reproductive – Female Breast pain 2 (1) 0 Dysmenorrhea 2 (1) 0 Vision Abnormal vision 2 (1) 0 In the 8-week, double-blind period of the comparative trial with bromocriptine, cabergoline (at a dose of 0.5 mg twice weekly) was discontinued because of an adverse event in 4 of 221 patients (2%) while bromocriptine (at a dose of 2.5 mg two times a day) was discontinued in 14 of 231 patients (6%). The most common reasons for discontinuation from cabergoline were headache, nausea and vomiting (3, 2, and 2 patients, respectively); the most common reasons for discontinuation from bromocriptine were nausea, vomiting, headache, and dizziness or vertigo (10, 3, 3, and 3 patients, respectively). The incidence of the most common adverse events during the double-blind portion of the comparative trial with bromocriptine is presented in the following table. Incidence of Reported Adverse Events During the 8-Week, Double-Blind Period of the Comparative Trial With Bromocriptine Adverse Event Reported at ≥1% for cabergoline Cabergoline (n=221) Bromocriptine (n=231) Number (percent) Gastrointestinal Nausea 63 (29) 100 (43) Constipation 15 (7) 21 (9) Abdominal pain 12 (5) 19 (8) Dyspepsia 11 (5) 16 (7) Vomiting 9 (4) 16 (7) Dry mouth 5 (2) 2 (1) Diarrhea 4 (2) 7 (3) Flatulence 4 (2) 3 (1) Throat irritation 2 (1) 0 Toothache 2 (1) 0 Central and Peripheral Nervous System Headache 58 (26) 62 (27) Dizziness 38 (17) 42 (18) Vertigo 9 (4) 10 (4) Paresthesia 5 (2) 6 (3) Body As a Whole Asthenia 13 (6) 15 (6) Fatigue 10 (5) 18 (8) Syncope 3 (1) 3 (1) Influenza-like symptoms 2 (1) 0 Malaise 2 (1) 0 Periorbital edema 2 (1) 2 (1) Peripheral edema 2 (1) 1 Psychiatric Depression 7 (3) 5 (2) Somnolence 5 (2) 5 (2) Anorexia 3 (1) 3 (1) Anxiety 3 (1) 3 (1) Insomnia 3 (1) 2 (1) Impaired concentration 2 (1) 1 Nervousness 2 (1) 5 (2) Cardiovascular Hot flashes 6 (3) 3 (1) Hypotension 3 (1) 4 (2) Dependent edema 2 (1) 1 Palpitation 2 (1) 5 (2) Reproductive – Female Breast pain 5 (2) 8 (3) Dysmenorrhea 2 (1) 1 Skin and Appendages Acne 3 (1) 0 Pruritus 2 (1) 1 Musculoskeletal Pain 4 (2) 6 (3) Arthralgia 2 (1) 0 Respiratory Rhinitis 2 (1) 9 (4) Vision Abnormal vision 2 (1) 2 (1) Other adverse events that were reported at an incidence of <1.0% in the overall clinical studies follow. Body As a Whole: facial edema, influenza-like symptoms, malaise Cardiovascular System: hypotension, syncope, palpitations Digestive System: dry mouth, flatulence, diarrhea, anorexia Metabolic and Nutritional System: weight loss, weight gain Nervous System: somnolence, nervousness, paresthesia, insomnia, anxiety Respiratory System: nasal stuffiness, epistaxis Skin and Appendages: acne, pruritus Special Senses: abnormal vision Urogenital System: dysmenorrhea, increased libido The safety of cabergoline has been evaluated in approximately 1,200 patients with Parkinson’s disease in controlled and uncontrolled studies at dosages of up to 11.5 mg/day which greatly exceeds the maximum recommended dosage of cabergoline for hyperprolactinemic disorders. In addition to the adverse events that occurred in the patients with hyperprolactinemic disorders, the most common adverse events in patients with Parkinson’s disease were dyskinesia, hallucinations, confusion, and peripheral edema. Heart failure, pleural effusion, pulmonary fibrosis, and gastric or duodenal ulcer occurred rarely. One case of constrictive pericarditis has been reported. Post-marketing Surveillance data The following events have been reported in association with cabergoline: cardiac valvulopathy and extracardiac fibrotic reactions Other events have been reported in association with cabergoline: impulse control/compulsive behavior symptoms, including hypersexuality, increased libido and pathological gambling (See PRECAUTIONS, Psychiatric ). In addition, cases of alopecia, aggression, and psychotic disorder have been reported in patients taking cabergoline. Some of these reports have been in patients who have had prior adverse reactions to dopamine agonist products. To report SUSPECTED ADVERSE REACTIONS, contact SOLA Pharmaceuticals at 1-1-866-747-7365 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS Cabergoline Tablets, USP are contraindicated in patients with Uncontrolled hypertension or known hypersensitivity to ergot derivatives. History of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (See WARNINGS ). History of pulmonary, pericardial, or retroperitoneal fibrotic disorders (See WARNINGS )."],"drug_interactions":["Drug Interactions: Cabergoline should not be administered concurrently with D 2 -antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide."],"how_supplied_table":["<table width=\"75%\" styleCode=\"Noautorules\"><col width=\"50%\"/><col width=\"50%\"/><tbody><tr><td valign=\"top\"><paragraph> Bottles of 8 tablets</paragraph></td><td align=\"left\" valign=\"top\"><paragraph>NDC 70512-860-08</paragraph></td></tr></tbody></table>"],"general_precautions":["General: Initial doses higher than 1.0 mg may produce orthostatic hypotension. Care should be exercised when administering cabergoline with other medications known to lower blood pressure. Postpartum Lactation Inhibition or Suppression: Cabergoline is not indicated for the inhibition or suppression of physiologic lactation. Use of bromocriptine, another dopamine agonist for this purpose, has been associated with cases of hypertension, stroke, and seizures. Hepatic Impairment: Since cabergoline is extensively metabolized by the liver, caution should be used, and careful monitoring exercised, when administering cabergoline to patients with hepatic impairment. Psychiatric: Impulse control/compulsive behaviors, including pathological gambling, increased libido, and hypersexuality, have been reported in patients treated with dopamine agonists including cabergoline. This has been generally reversible upon reduction of the dose or treatment discontinuation (see Post-marketing Surveillance data ). Prescribers should consider dose reduction or stopping the medication if a patient develops such urges while taking cabergoline."],"storage_and_handling":["STORAGE Store at controlled room temperature 20° to 25° C (68° to 77° F) [see USP Controlled Room Temperature]. Dispense in original container. Distributed by: SOLA Pharmaceuticals Baton Rouge, LA 70810"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Mechanism of Action: The secretion of prolactin by the anterior pituitary is mainly under hypothalamic inhibitory control, likely exerted through release of dopamine by tuberoinfundibular neurons. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D 2 receptors. Results of in vitro studies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. Cabergoline decreased serum prolactin levels in reserpinized rats. Receptor-binding studies indicate that cabergoline has low affinity for dopamine D 1 , a 1 - and a 2 -adrenergic, and 5-HT 1 - and 5-HT 2 -serotonin receptors. Clinical Studies: The prolactin-lowering efficacy of cabergoline was demonstrated in hyperprolactinemic women in two randomized, double-blind, comparative studies, one with placebo and the other with bromocriptine. In the placebo-controlled study (placebo n=20; cabergoline n=168), cabergoline produced a dose-related decrease in serum prolactin levels with prolactin normalized after 4 weeks of treatment in 29%, 76%, 74% and 95% of the patients receiving 0.125, 0.5, 0.75, and 1 mg twice weekly, respectively. In the 8-week, double-blind period of the comparative trial with bromocriptine (cabergoline n=223; bromocriptine n=236 in the intent-to-treat analysis), prolactin was normalized in 77% of the patients treated with cabergoline at 0.5 mg twice weekly compared with 59% of those treated with bromocriptine at 2.5 mg twice daily. Restoration of menses occurred in 77% of the women treated with cabergoline, compared with 70% of those treated with bromocriptine. Among patients with galactorrhea, this symptom disappeared in 73% of those treated with cabergoline compared with 56% of those treated with bromocriptine. Pharmacokinetics Absorption: Following single oral doses of 0.5 mg to 1.5 mg given to 12 healthy adult volunteers, mean peak plasma levels of 30 to 70 picograms (pg)/mL of cabergoline were observed within 2 to 3 hours. Over the 0.5 to 7 mg dose range, cabergoline plasma levels appeared to be dose-proportional in 12 healthy adult volunteers and nine adult parkinsonian patients. A repeat-dose study in 12 healthy volunteers suggests that steady-state levels following a once-weekly dosing schedule are expected to be twofold to threefold higher than after a single dose. The absolute bioavailability of cabergoline is unknown. A significant fraction of the administered dose undergoes a first-pass effect. The elimination half-life of cabergoline estimated from urinary data of 12 healthy subjects ranged between 63 to 69 hours. The prolonged prolactin-lowering effect of cabergoline may be related to its slow elimination and long half-life. Distribution: In animals, based on total radioactivity, cabergoline (and/or its metabolites) has shown extensive tissue distribution. Radioactivity in the pituitary exceeded that in plasma by >100-fold and was eliminated with a half-life of approximately 60 hours. This finding is consistent with the long-lasting prolactin-lowering effect of the drug. Whole body autoradiography studies in pregnant rats showed no fetal uptake but high levels in the uterine wall. Significant radioactivity (parent plus metabolites) detected in the milk of lactating rats suggests a potential for exposure to nursing infants. The drug is extensively distributed throughout the body. Cabergoline is moderately bound (40% to 42%) to human plasma proteins in a concentration-independent manner. Concomitant dosing of highly protein-bound drugs is unlikely to affect its disposition. Metabolism: In both animals and humans, cabergoline is extensively metabolized, predominately via hydrolysis of the acylurea bond or the urea moiety. Cytochrome P-450 mediated metabolism appears to be minimal. Cabergoline does not cause enzyme induction and/or inhibition in the rat. Hydrolysis of the acylurea or urea moiety abolishes the prolactin-lowering effect of cabergoline, and major metabolites identified thus far do not contribute to the therapeutic effect. Excretion: After oral dosing of radioactive cabergoline to five healthy volunteers, approximately 22% and 60% of the dose was excreted within 20 days in the urine and feces, respectively. Less than 4% of the dose was excreted unchanged in the urine. Nonrenal and renal clearances for cabergoline are about 3.2 L/min and 0.08 L/min, respectively. Urinary excretion in hyperprolactinemic patients was similar. Special Populations Renal Insufficiency: The pharmacokinetics of cabergoline were not altered in 12 patients with moderate-to severe renal insufficiency as assessed by creatinine clearance. Hepatic Insufficiency: In 12 patients with mild-to-moderate hepatic dysfunction (Child-Pugh score £10), no effect on mean cabergoline C max or area under the plasma concentration curve (AUC) was observed. However, patients with severe insufficiency (Child-Pugh score >10) show a substantial increase in the mean cabergoline C max and AUC, and thus necessitate caution. Elderly: Effect of age on the pharmacokinetics of cabergoline has not been studied. Food-Drug Interaction: In 12 healthy adult volunteers, food did not alter cabergoline kinetics. Pharmacodynamics Dose response with inhibition of plasma prolactin, onset of maximal effect, and duration of effect has been documented following single cabergoline doses to healthy volunteers (0.05 to 1.5 mg) and hyperprolactinemic patients (0.3 to 1 mg). In volunteers, prolactin inhibition was evident at doses >0.2 mg, while doses ≥ 0.5 mg caused maximal suppression in most subjects. Higher doses produce prolactin suppression in a greater proportion of subjects and with an earlier onset and longer duration of action. In 12 healthy volunteers, 0.5, 1 and 1.5 mg doses resulted in complete prolactin inhibition, with a maximum effect within 3 hours in 92% to 100% of subjects after the 1 and 1.5 mg doses compared with 50% of subjects after the 0.5 mg dose. In hyperprolactinemic patients (n=51), the maximal prolactin decrease after a 0.6 mg single dose of cabergoline was comparable to 2.5 mg bromocriptine; however, the duration of effect was markedly longer (14 days vs. 24 hours). The time to maximal effect was shorter for bromocriptine than cabergoline (6 hours vs. 48 hours). In 72 healthy volunteers, single or multiple doses (up to 2 mg) of cabergoline resulted in selective inhibition of prolactin with no apparent effect on other anterior pituitary hormones (GH, FSH, LH, ACTH, and TSH) or cortisol."],"indications_and_usage":["INDICATIONS AND USAGE Cabergoline Tablets, USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas."],"adverse_reactions_table":["<table ID=\"SPLSERV-9e2b6380-2b34-466f-a3cc-f82636b3e73b\" width=\"80%\"><caption>Incidence of Reported Adverse Events During the 4-Week, Double-Blind, Placebo-Controlled Trial</caption><col width=\"46%\"/><col width=\"27%\"/><col width=\"27%\"/><thead><tr><th align=\"center\" styleCode=\"Lrule Toprule\" valign=\"middle\"><content styleCode=\"bold\">Adverse Event</content><footnote ID=\"SPLSERV-b4d93649-33b3-471b-80b8-59f291cf9875\">Reported at &#x2265;1% for cabergoline</footnote></th><th align=\"center\" styleCode=\"Botrule Lrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Cabergoline</content> <content styleCode=\"bold\">(n=168)</content> <content styleCode=\"bold\">0.125 to 1 mg two times a week</content></th><th align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(n=20)</content></th></tr><tr><th align=\"left\" styleCode=\"Botrule Lrule\" valign=\"top\"><content styleCode=\"bold\"> </content></th><th align=\"center\" colspan=\"2\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Number (percent)</content></th></tr></thead><tbody><tr><td styleCode=\"Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"Lrule Toprule\" valign=\"top\"> </td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"top\"> </td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>45 (27)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>4 (20)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>16 (10)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Abdominal pain</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>9 (5)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>1 (5)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>4 (2)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>4 (2)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Central and Peripheral Nervous System</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"> </td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"> </td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>43 (26)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>5 (25)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Dizziness</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>25 (15)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>1 (5)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Paresthesia</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Vertigo</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Body As a Whole</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"> </td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"/></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Asthenia</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>15 (9)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>2 (10)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Fatigue</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>12 (7)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Hot flashes</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>1 (5)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Psychiatric</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Somnolence</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>9 (5)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>1 (5)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Depression</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>5 (3)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>1 (5)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Nervousness</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>4 (2)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Autonomic Nervous System</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Postural hypotension</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>6 (4)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Reproductive &#x2013; Female</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Breast pain</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Dysmenorrhea</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Vision</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Abnormal vision</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>","<table ID=\"SPLSERV-1c272672-5b12-49d6-8f8d-c4685c98d88c\" width=\"80%\"><caption>Incidence of Reported Adverse Events During the 8-Week, Double-Blind Period of the Comparative Trial With Bromocriptine</caption><col width=\"50%\"/><col width=\"25%\"/><col width=\"25%\"/><thead><tr><th align=\"center\" styleCode=\"Lrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Adverse Event</content><footnote ID=\"SPLSERV-194a5312-c059-4019-b9f9-7a0a4f242dc7\">Reported at &#x2265;1% for cabergoline</footnote></th><th align=\"center\" styleCode=\"Botrule Lrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Cabergoline</content> <content styleCode=\"bold\">(n=221)</content></th><th align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Bromocriptine</content> <content styleCode=\"bold\">(n=231)</content></th></tr><tr><th align=\"left\" styleCode=\"Botrule Lrule\" valign=\"top\"><content styleCode=\"bold\"> </content></th><th align=\"center\" colspan=\"2\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Number (percent)</content></th></tr></thead><tbody><tr><td styleCode=\"Lrule Toprule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Gastrointestinal</content></paragraph></td><td align=\"center\" styleCode=\"Lrule Toprule\" valign=\"top\"> </td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"top\"> </td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>63 (29)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>100 (43)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>15 (7)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>21 (9)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Abdominal pain</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>12 (5)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>19 (8)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>11 (5)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>16 (7)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>9 (4)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>16 (7)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Dry mouth</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>5 (2)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>4 (2)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>7 (3)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Flatulence</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>4 (2)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>3 (1)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Throat irritation</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Toothache</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Central and Peripheral Nervous System</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"> </td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>58 (26)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>62 (27)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Dizziness</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>38 (17)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>42 (18)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Vertigo</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>9 (4)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>10 (4)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Paresthesia</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>5 (2)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>6 (3)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Body As a Whole</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Asthenia</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>13 (6)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>15 (6)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Fatigue</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>10 (5)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>18 (8)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Syncope</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>3 (1)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>3 (1)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Influenza-like symptoms</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Malaise</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Periorbital edema</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Peripheral edema</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Psychiatric</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Depression</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>7 (3)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>5 (2)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Somnolence</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>5 (2)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>5 (2)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Anorexia</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>3 (1)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>3 (1)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Anxiety</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>3 (1)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>3 (1)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Insomnia</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>3 (1)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Impaired concentration</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Nervousness</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>5 (2)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Cardiovascular</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Hot flashes</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>6 (3)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>3 (1)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Hypotension</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>3 (1)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>4 (2)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Dependent edema</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Palpitation</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>5 (2)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Reproductive &#x2013; Female</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Breast pain</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>5 (2)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>8 (3)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Dysmenorrhea</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Skin and Appendages</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Acne</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>3 (1)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Pruritus</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Musculoskeletal</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph> Pain</paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph>4 (2)</paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph>6 (3)</paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Arthralgia</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Respiratory</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Rhinitis</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>9 (4)</paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"><paragraph><content styleCode=\"underline\">Vision</content></paragraph></td><td align=\"center\" styleCode=\"Lrule\" valign=\"top\"><paragraph> </paragraph></td><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><paragraph> </paragraph></td></tr><tr><td styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph> Abnormal vision</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><paragraph>2 (1)</paragraph></td></tr></tbody></table>"],"information_for_patients":["Information for Patients: Patients should be instructed to notify their physician if they suspect they are pregnant, become pregnant, or intend to become pregnant during therapy. A pregnancy test should be done if there is any suspicion of pregnancy and continuation of treatment should be discussed with their physician. Patients should notify their physician if they develop shortness of breath, persistent cough, difficulty with breathing when lying down, or swelling in their extremities. Patients should be alerted to the possibility that patients may experience intense urges to spend money uncontrollably, intense urges to gamble, increased sexual urges, and other intense urges and the inability to control these urges while taking cabergoline. Advise patients to inform their healthcare provider if they develop new or increased uncontrolled spending, gambling urges, sexual urges, or other urges while being treated with cabergoline (see PRECAUTIONS )."],"spl_unclassified_section":[""],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The recommended dosage of Cabergoline Tablets, USP for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient’s serum prolactin level. Before initiating treatment, cardiovascular evaluation should be performed and echocardiography should be considered to assess for valvular disease. Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient's response to each dosage level. If the patient does not respond adequately, and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered. Patients receiving long term treatment with Cabergoline should undergo periodic assessment of their cardiac status and echocardiography should be considered. After a normal serum prolactin level has been maintained for 6 months, cabergoline may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with cabergoline should be reinstituted. The durability of efficacy beyond 24 months of therapy with cabergoline has not been established."],"spl_product_data_elements":["Cabergoline cabergoline CITRIC ACID MONOHYDRATE CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE CABERGOLINE CABERGOLINE P;673"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC 70512- 860 -08 Cabergoline Tablets, USP 0.5 mg 8 Tablets Rx only Sola Pharmaceuticals Each tablet contains: Cabergoline, USP ......... 0.5 mg USUAL DOSAGE: See accompanying product literature. KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN. Dispense in original container Store at Controlled Room Temperature 20° to 25°C (68° to 77°F) (see USP). R02/23 LCS-002-01-01 Distributed by: SOLA Pharmaceuticals, LLC Baton Rouge, LA 70810 label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenicity studies were conducted in mice and rats with cabergoline given by gavage at doses up to 0.98 mg/kg/day and 0.32 mg/kg/day, respectively. These doses are 7 times and 4 times the maximum recommended human dose calculated on a body surface area basis using total mg/m 2 /week in rodents and mg/m 2 /week for a 50 kg human. There was a slight increase in the incidence of cervical and uterine leiomyomas and uterine leiomyosarcomas in mice. In rats, there was a slight increase in malignant tumors of the cervix and uterus and interstitial cell adenomas. The occurrence of tumors in female rodents may be related to the prolonged suppression of prolactin secretion because prolactin is needed in rodents for the maintenance of the corpus luteum. In the absence of prolactin, the estrogen/progesterone ratio is increased, thereby increasing the risk for uterine tumors. In male rodents, the decrease in serum prolactin levels was associated with an increase in serum luteinizing hormone, which is thought to be a compensatory effect to maintain testicular steroid synthesis. Since these hormonal mechanisms are thought to be species-specific, the relevance of these tumors to humans is not known. The mutagenic potential of cabergoline was evaluated and found to be negative in a battery of in vitro tests. These tests included the bacterial mutation (Ames) test with Salmonella typhimurium , the gene mutation assay with Schizosaccharomyces pombe P1 and V79 Chinese hamster cells, DNA damage and repair in Saccharomyces cerevisiae D4 , and chromosomal aberrations in human lymphocytes. Cabergoline was also negative in the bone marrow micronucleus test in the mouse. In female rats, a daily dose of 0.003 mg/kg for 2 weeks prior to mating and throughout the mating period inhibited conception. This dose represents approximately 1/28 the maximum recommended human dose calculated on a body surface area basis using total mg/m 2 /week in rats and mg/m 2 /week for a 50 kg human."]},"tags":[{"label":"Ergot Derivative","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D(2) dopamine receptor","category":"target"},{"label":"DRD2","category":"gene"},{"label":"DRD3","category":"gene"},{"label":"HTR2B","category":"gene"},{"label":"G02CB03","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Hyperprolactinemia","category":"indication"},{"label":"Prevention of ovarian hyperstimulation syndrome","category":"indication"},{"label":"Pfizer Japan Inc.","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Anti-Dyskinesia Agents","category":"pharmacology"},{"label":"Antiparkinson Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Agonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"390 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"351 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"319 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"275 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"274 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"224 reports"},{"date":"","signal":"MALAISE","source":"FDA FAERS","actionTaken":"209 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"195 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"175 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"170 reports"}],"drugInteractions":[{"url":"/drug/clarithromycin","drug":"clarithromycin","action":"Avoid combination","effect":"May interact with Clarithromycin","source":"DrugCentral","drugSlug":"clarithromycin"},{"url":"/drug/conivaptan","drug":"conivaptan","action":"Avoid combination","effect":"May interact with Conivaptan","source":"DrugCentral","drugSlug":"conivaptan"},{"url":"/drug/mibefradil","drug":"mibefradil","action":"Avoid combination","effect":"May interact with Mibefradil Dihydrochloride","source":"DrugCentral","drugSlug":"mibefradil"},{"url":"/drug/nefazodone","drug":"nefazodone","action":"Avoid combination","effect":"May interact with Nefazodone","source":"DrugCentral","drugSlug":"nefazodone"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"≥27%","severity":"serious","_validated":true},{"effect":"Headache","drugRate":"26%","severity":"serious","_validated":true},{"effect":"Dizziness","drugRate":"18%","severity":"common","_validated":true},{"effect":"Constipation","drugRate":"≥9%","severity":"common","_validated":true},{"effect":"Abdominal pain","drugRate":"≥5%","severity":"common","_validated":true},{"effect":"Vomiting","drugRate":"≥4%","severity":"common","_validated":true},{"effect":"Asthenia","drugRate":"≥6%","severity":"common","_validated":true},{"effect":"Fatigue","drugRate":"≥5%","severity":"common","_validated":true},{"effect":"Dyspepsia","drugRate":"≥5%","severity":"common","_validated":true},{"effect":"Somnolence","drugRate":"≥5%","severity":"common","_validated":true},{"effect":"Depression","drugRate":"≥5%","severity":"common","_validated":true},{"effect":"Hot flashes","drugRate":"≥3%","severity":"mild","_validated":true},{"effect":"Postural hypotension","drugRate":"≥4%","severity":"mild","_validated":true},{"effect":"Dysmenorrhea","drugRate":"≥2%","severity":"mild","_validated":true},{"effect":"Abnormal vision","drugRate":"≥1%","severity":"mild","_validated":true},{"effect":"Paresthesia","drugRate":"≥1%","severity":"mild","_validated":true},{"effect":"Vertigo","drugRate":"≥1%","severity":"mild","_validated":true},{"effect":"Anorexia","drugRate":"≥1%","severity":"mild","_validated":true},{"effect":"Anxiety","drugRate":"≥1%","severity":"mild","_validated":true},{"effect":"Insomnia","drugRate":"≥1%","severity":"mild","_validated":true},{"effect":"Impaired concentration","drugRate":"≥1%","severity":"mild","_validated":true},{"effect":"Nervousness","drugRate":"≥1%","severity":"mild","_validated":true},{"effect":"Palpitation","drugRate":"≥1%","severity":"mild","_validated":true},{"effect":"Dependent edema","drugRate":"≥1%","severity":"mild","_validated":true},{"effect":"Pruritus","drugRate":"≥1%","severity":"mild","_validated":true},{"effect":"Arthralgia","drugRate":"≥1%","severity":"mild","_validated":true},{"effect":"Rhinitis","drugRate":"≥1%","severity":"mild","_validated":true},{"effect":"Facial edema","drugRate":"≥1%","severity":"mild","_validated":true}],"contraindications":["Breastfeeding (mother)","Disease of liver","Fibrosis of lung","Fibrosis of pericardium","Heart valve disorder","Hypertensive urgency","Occlusive Vascular Disease","Retroperitoneal fibrosis","Severe pre-eclampsia"],"specialPopulations":{"Pregnancy":"Teratogenic Effects: Category B. Reproduction studies have been performed with cabergoline in mice, rats, and rabbits administered by gavage. There were maternotoxic effects but no teratogenic effects in mice given cabergoline at doses up to mg/kg/day (approximately 55 times the maximum recommended human dose) ","Geriatric use":"Clinical studies of cabergoline did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function","Paediatric use":"Safety and effectiveness of cabergoline in pediatric patients have not been established.","Renal impairment":"The pharmacokinetics of cabergoline were not altered in 12 patients with moderate-to-severe renal insufficiency as assessed by creatinine clearance. Patients with severe insufficiency (Child-Pugh score 10) show substantial increase in the mean cabergoline Cmax and AUC, and thus necessitate caution.","Hepatic impairment":"In 12 patients with mild-to-moderate hepatic dysfunction (Child-Pugh score <= 10), no effect on mean cabergoline Cmax or area under the plasma concentration curve (AUC) was observed. However, patients with severe insufficiency (Child-Pugh score 10) show substantial increase in the mean cabergoline Cmax and AUC, and thus necessitate caution."}},"trials":[],"aliases":[],"company":"Pfizer Japan Inc.","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$1.7985/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$656","description":"CABERGOLINE 0.5 MG TABLET","retrievedDate":"2026-04-07"}],"_fixedAt":"2026-03-30T16:55:14.056648","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CABERGOLINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:18:22.734917+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Cabergoline","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:18:30.631504+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:18:29.276450+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:18:21.229852+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CABERGOLINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:18:30.068952+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:18:19.833195+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:18:19.833213+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:18:19.833218+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:18:31.556369+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dopamine D2 receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:18:30.630555+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201087/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:18:30.529380+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA076310","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:18:19.833221+00:00"}},"allNames":"dostinex","offLabel":[],"synonyms":["cabergoline","dostinex","galastop","cabaser","cabaseril"],"timeline":[{"date":"1996-12-23","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"1999-08-01","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Pfizer Japan Inc.)"},{"date":"2008-04-21","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 4 manufacturers approved"}],"aiSummary":"Dostinex (CABERGOLINE) is a small molecule ergot derivative that targets the D(2) dopamine receptor. It is used to treat hyperprolactinemia and prevent ovarian hyperstimulation syndrome. Originally developed by Pfizer Japan Inc., it is now owned by Pfizer and has been FDA-approved since 1996. Dostinex is available as a generic medication, with multiple manufacturers, and is no longer patented. As an ergot derivative, it has a relatively long half-life of 60 hours and moderate bioavailability of 65%.","brandName":"Dostinex","ecosystem":[{"indication":"Hyperprolactinemia","otherDrugs":[{"name":"bromocriptine","slug":"bromocriptine","company":"Us Pharms Holdings I"}],"globalPrevalence":1494000000},{"indication":"Prevention of ovarian hyperstimulation syndrome","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"D(2) dopamine receptor","novelty":"Follow-on","targets":[{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor","isPrimary":true,"activityType":"Ki","activityValue":9.2},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"HTR1D","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1D","protein":"5-hydroxytryptamine receptor 1D"},{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"},{"gene":"DRD5","source":"DrugCentral","target":"D(1B) dopamine receptor","protein":"D(1B) dopamine receptor"},{"gene":"DRD4","source":"DrugCentral","target":"D(4) dopamine receptor","protein":"D(4) dopamine receptor"}],"modality":"Small Molecule","drugClass":"Ergot Derivative [EPC]","explanation":"","oneSentence":"","technicalDetail":"Dostinex acts as a dopamine D(2) receptor antagonist, which inhibits the release of prolactin from the anterior pituitary gland, thereby reducing serum prolactin levels."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Cabergoline","title":"Cabergoline","extract":"Cabergoline, sold under the brand name Dostinex among others, is a dopaminergic medication used in the treatment of high prolactin levels, prolactinomas, Parkinson's disease, and for other indications. It is taken by mouth.","wiki_history":"==History==\nCabergoline was first synthesized by scientists working for the Italian drug company Farmitalia-Carlo Erba in Milan who were experimenting with semisynthetic derivatives of the ergot alkaloids, and a patent application was filed in 1980.  The first publication was a scientific abstract at the Society for Neuroscience meeting in 1991.\n\nFarmitalia-Carlo Erba was acquired by Pharmacia in 1993, which in turn was acquired by Pfizer in 2003.\n\nCabergoline was first marketed in The Netherlands as Dostinex in 1992. It went generic in late 2005 following US patent expiration.","wiki_society_and_culture":"==Society and culture==\n===Brand names===\nBrand names of cabergoline include Cabaser, Dostinex, Galastop (veterinary), and Kelactin (veterinary), among others."},"commercial":{"launchDate":"1996","_launchSource":"DrugCentral (FDA 1996-12-23, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/460","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CABERGOLINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CABERGOLINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Cabergoline","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:06:18.170830","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:18:35.633677+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"bromocriptine","drugSlug":"bromocriptine","fdaApproval":"1978-06-28","patentExpiry":"Jun 7, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"cabergoline","indications":{"approved":[{"name":"Hyperprolactinemia","source":"DrugCentral","snomedId":237662005,"regulator":"FDA","eligibility":"idiopathic or due to pituitary adenomas","globalPrevalence":1494000000,"prevalenceMethod":"ai-extracted","prevalenceSource":"Int J Environ Res Public Health, 2020 (PMID:33171973)"},{"name":"Prevention of ovarian hyperstimulation syndrome","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_fixedFields":["primaryTarget"],"currentOwner":"Pfizer","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"bromocriptine","brandName":"bromocriptine","genericName":"bromocriptine","approvalYear":"1978","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07492160","phase":"PHASE2","title":"Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms","status":"RECRUITING","sponsor":"Maimonides Medical Center","startDate":"2026-03-16","conditions":["Pregnancy","Abortion"],"enrollment":348,"completionDate":"2028-04"},{"nctId":"NCT07463235","phase":"PHASE3","title":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-04","conditions":["Prolactinoma","Prolactin Excess"],"enrollment":70,"completionDate":"2029-12-20"},{"nctId":"NCT07043322","phase":"PHASE2","title":"Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-06-30","conditions":["Gynecologic Disease"],"enrollment":150,"completionDate":"2026-11-20"},{"nctId":"NCT07386080","phase":"PHASE4","title":"Carbergoline for Antipsychotic Induced Hyperprolactinemia.","status":"NOT_YET_RECRUITING","sponsor":"Zealand University Hospital","startDate":"2026-05-01","conditions":["Scizophrenia"],"enrollment":146,"completionDate":"2029-05-01"},{"nctId":"NCT03928288","phase":"PHASE2","title":"Cabergoline for the Treatment of Chronic Pain Due to Endometriosis","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2019-12-02","conditions":["Endometriosis"],"enrollment":129,"completionDate":"2026-01-14"},{"nctId":"NCT07255911","phase":"NA","title":"Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS","status":"RECRUITING","sponsor":"Mst.Sumyara Khatun","startDate":"2025-02-07","conditions":["PCOS"],"enrollment":72,"completionDate":"2026-06-30"},{"nctId":"NCT06909123","phase":"PHASE2","title":"A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-07","conditions":["Lactation Suppressed"],"enrollment":36,"completionDate":"2027-07"},{"nctId":"NCT07072910","phase":"PHASE2","title":"Cabergoline for Episodic Migraine","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-12","conditions":["Migraine"],"enrollment":150,"completionDate":"2028-09-01"},{"nctId":"NCT07008417","phase":"PHASE1","title":"A Study on Bioequivalence of Cabergoline Tablets in Human Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-06-30","conditions":["Hyperprolactinemia"],"enrollment":72,"completionDate":"2026-05-06"},{"nctId":"NCT06029673","phase":"PHASE2","title":"Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss","status":"COMPLETED","sponsor":"Stanford University","startDate":"2024-02-07","conditions":["Lactation Suppressed"],"enrollment":69,"completionDate":"2025-07-01"},{"nctId":"NCT07124221","phase":"PHASE3","title":"A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-09-12","conditions":["Hyperprolactinemia"],"enrollment":382,"completionDate":"2026-12-30"},{"nctId":"NCT07045935","phase":"PHASE4","title":"Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-09-16","conditions":["Prolactinoma"],"enrollment":60,"completionDate":"2029-12-31"},{"nctId":"NCT07168837","phase":"NA","title":"Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2023-01-10","conditions":["PCOS (Polycystic Ovary Syndrome)"],"enrollment":100,"completionDate":"2024-05-10"},{"nctId":"NCT07034859","phase":"PHASE4","title":"Cabergoline in the Management of Nonfunctioning Pituitary Adenoma","status":"ENROLLING_BY_INVITATION","sponsor":"National Taiwan University Hospital","startDate":"2024-05-20","conditions":["Pituitary Adenoma","MRI","RCT"],"enrollment":30,"completionDate":"2028-12-31"},{"nctId":"NCT02288962","phase":"PHASE3","title":"Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Olavs Hospital","startDate":"2014-11","conditions":["Pituitary Neoplasms","Adenoma"],"enrollment":60,"completionDate":"2028-12"},{"nctId":"NCT06333691","phase":"NA","title":"Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin","status":"COMPLETED","sponsor":"Minia University","startDate":"2022-10-01","conditions":["Ovarian Hyperstimulation Syndrome"],"enrollment":180,"completionDate":"2024-02-15"},{"nctId":"NCT01794793","phase":"PHASE4","title":"Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies","status":"COMPLETED","sponsor":"RECORDATI GROUP","startDate":"2013-06-10","conditions":["Cushing's Disease","Acromegaly","Neuroendocrine Tumors","Pituitary Tumors","Ectopic ACTH Secreting (EAS) Tumors","Dumping Syndrome","Prostate Cancer","Melanoma Negative for bRAF","Melanoma Negative for nRAS"],"enrollment":337,"completionDate":"2023-07-25"},{"nctId":"NCT06560814","phase":"PHASE2","title":"Non-surgical Interventions for Infertility in Endometriosis","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2020-07-01","conditions":["Endometriosis","Infertility, Female"],"enrollment":18,"completionDate":"2021-06-30"},{"nctId":"NCT06123026","phase":"PHASE4","title":"Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2023-12-18","conditions":["Lactation Suppressed","Second Trimester Abortion"],"enrollment":200,"completionDate":"2024-06-30"},{"nctId":"NCT05525611","phase":"NA","title":"Cabergoline as a Preventive Treatment for Chronic Migraine","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2022-09-05","conditions":["Migraine"],"enrollment":36,"completionDate":"2023-08-08"},{"nctId":"NCT04701333","phase":"PHASE2","title":"Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss","status":"COMPLETED","sponsor":"Stanford University","startDate":"2021-04-01","conditions":["Lactation Suppressed"],"enrollment":73,"completionDate":"2023-03-01"},{"nctId":"NCT05981742","phase":"PHASE2","title":"Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS","status":"COMPLETED","sponsor":"Al-Rasheed University College","startDate":"2022-09-21","conditions":["Polycystic Ovary Syndrome"],"enrollment":75,"completionDate":"2023-03-31"},{"nctId":"NCT04262024","phase":"PHASE1","title":"Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia.","status":"COMPLETED","sponsor":"Woman's Health University Hospital, Egypt","startDate":"2020-02-01","conditions":["Health Education"],"enrollment":120,"completionDate":"2023-05-01"},{"nctId":"NCT05024422","phase":"NA","title":"Lactation Inhibition, the Efficiency of Vitamin B6 Versus Cabergoline","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2021-12-31","conditions":["Lactation Suppressed"],"enrollment":89,"completionDate":"2022-11-07"},{"nctId":"NCT02685709","phase":"PHASE3","title":"Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly","status":"COMPLETED","sponsor":"Chiasma, Inc.","startDate":"2016-02","conditions":["Acromegaly"],"enrollment":146,"completionDate":"2021-08"},{"nctId":"NCT03965572","phase":"","title":"Factors and Outcomes Associated With Postpartum Cabergoline Use","status":"UNKNOWN","sponsor":"Laniado Hospital","startDate":"2019-06-07","conditions":["Lactation Suppressed","Cabergoline Adverse Reaction","Postpartum DVT","Postpartum Depression"],"enrollment":100,"completionDate":"2023-05-12"},{"nctId":"NCT04096027","phase":"PHASE4","title":"Cabergoline Before or After Oocyte Collection for Follicular Resolution","status":"COMPLETED","sponsor":"Fertility Center of Las Vegas","startDate":"2019-09-23","conditions":["Infertility, Female"],"enrollment":70,"completionDate":"2021-06-10"},{"nctId":"NCT01915303","phase":"PHASE2","title":"Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-06","conditions":["Cushings Disease"],"enrollment":68,"completionDate":"2019-09-04"},{"nctId":"NCT04107480","phase":"PHASE4","title":"PRolaCT - Three Prolactinoma RCTs","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2019-06-21","conditions":["Prolactinoma","Prolactin-Producing Pituitary Tumor"],"enrollment":880,"completionDate":"2026-03-31"},{"nctId":"NCT03457389","phase":"NA","title":"Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2018-02-22","conditions":["Pituitary Adenoma","Prolactinoma","Pituitary Tumor","Recurrence Tumor"],"enrollment":68,"completionDate":"2024-12-31"},{"nctId":"NCT02542410","phase":"PHASE2","title":"Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2016-05","conditions":["Endometriosis"],"enrollment":10,"completionDate":"2018-09"},{"nctId":"NCT01443949","phase":"","title":"Teenagers, Drug Addiction, and Reward and Impulse Control","status":"WITHDRAWN","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2011-09-11","conditions":["Adolescents","Conduct Disorder","Vulnerability to Substance Addicition"],"enrollment":0,"completionDate":"2013-04-04"},{"nctId":"NCT01730729","phase":"EARLY_PHASE1","title":"Cabergoline in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2013-02-11","conditions":["Recurrent Breast Cancer","Stage IV Breast Cancer"],"enrollment":20,"completionDate":"2017-10-27"},{"nctId":"NCT04038749","phase":"NA","title":"Satisfaction of Patients With the Chosen Method of Inhibition of Lactation","status":"UNKNOWN","sponsor":"Żelazna Medical Centre, LLC","startDate":"2019-06-16","conditions":["Lactation Suppressed"],"enrollment":90,"completionDate":"2022-12-31"},{"nctId":"NCT02875587","phase":"PHASE2","title":"Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome","status":"COMPLETED","sponsor":"Aljazeera Hospital","startDate":"2016-10","conditions":["OHSS"],"enrollment":170,"completionDate":"2018-12"},{"nctId":"NCT03714763","phase":"NA","title":"Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)","status":"UNKNOWN","sponsor":"Zhebao Wu","startDate":"2018-11-01","conditions":["Pituitary Adenoma"],"enrollment":50,"completionDate":"2022-01-31"},{"nctId":"NCT03400865","phase":"NA","title":"Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas","status":"UNKNOWN","sponsor":"Zhebao Wu","startDate":"2018-10-25","conditions":["Resistance, Disease","Prolactinoma"],"enrollment":30,"completionDate":"2020-12-30"},{"nctId":"NCT03313661","phase":"PHASE3","title":"Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2017-10-14","conditions":["Diabetes"],"enrollment":60,"completionDate":"2020-12"},{"nctId":"NCT01535859","phase":"PHASE3","title":"Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers","status":"COMPLETED","sponsor":"KK Women's and Children's Hospital","startDate":"2012-04","conditions":["Ovarian Hyperstimulation Syndrome"],"enrollment":46,"completionDate":"2016-06"},{"nctId":"NCT03549741","phase":"PHASE2,PHASE3","title":"Cabergoline As An Adjuvant To Clomiphene Citrate For Management Of Unexplained Infertility","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-07","conditions":["Infertility"],"enrollment":120,"completionDate":"2019-11"},{"nctId":"NCT02620605","phase":"PHASE3","title":"The Influence of Timing of Cabergoline Initiation on Prevention of OHSS","status":"UNKNOWN","sponsor":"Mona M Shaban","startDate":"2017-12-20","conditions":["Ovarian Hyperstimulation Syndrome"],"enrollment":75,"completionDate":"2019-04"},{"nctId":"NCT03473613","phase":"PHASE3","title":"Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention","status":"COMPLETED","sponsor":"Benha University","startDate":"2014-10-01","conditions":["Ovarian Hyperstimulation"],"enrollment":230,"completionDate":"2017-04-15"},{"nctId":"NCT00699530","phase":"","title":"Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment","status":"WITHDRAWN","sponsor":"University of Aarhus","startDate":"2008-05","conditions":["Hyperprolactinemia","Insulin Resistance"],"enrollment":0,"completionDate":"2016-11"},{"nctId":"NCT00652873","phase":"PHASE1","title":"Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2001-07","conditions":["To Determine Bioequivalence Under Fed Conditions"],"enrollment":24,"completionDate":"2001-12"},{"nctId":"NCT03271918","phase":"PHASE3","title":"Cabergoline in Nonfunctioning Pituitary Adenomas","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-02-01","conditions":["Pituitary Adenoma","Nonfunctioning Pituitary Adenoma"],"enrollment":140,"completionDate":"2017-08-01"},{"nctId":"NCT03263299","phase":"PHASE4","title":"Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2017-08","conditions":["Invitro Fertilization"],"enrollment":120,"completionDate":"2018-09"},{"nctId":"NCT01984320","phase":"NA","title":"Cabergoline and Coasting to Prevent OHSS","status":"COMPLETED","sponsor":"Cairo University","startDate":"2013-10","conditions":["OHSS"],"enrollment":300,"completionDate":"2015-07"},{"nctId":"NCT00376064","phase":"PHASE4","title":"Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-03","conditions":["Acromegaly"],"enrollment":20,"completionDate":""},{"nctId":"NCT01278342","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":["Acromegaly"],"enrollment":70,"completionDate":"2009-11"},{"nctId":"NCT02271360","phase":"PHASE2,PHASE3","title":"Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome","status":"COMPLETED","sponsor":"Benha University","startDate":"2014-04","conditions":["Infertility"],"enrollment":200,"completionDate":"2015-12"},{"nctId":"NCT00033111","phase":"PHASE2","title":"A Study of Cabergoline for the Treatment of Cocaine Dependence - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2001-06","conditions":["Cocaine-Related Disorders","Substance-Related Disorders"],"enrollment":140,"completionDate":"2004-04"},{"nctId":"NCT02306564","phase":"PHASE2,PHASE3","title":"Effect of Cabergoline on Endometrial Vascularity During IntraCytoplasmic Sperm Injection","status":"UNKNOWN","sponsor":"Kasr El Aini Hospital","startDate":"2014-12","conditions":["Infertility"],"enrollment":150,"completionDate":"2017-12"},{"nctId":"NCT01620138","phase":"PHASE2,PHASE3","title":"Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas","status":"COMPLETED","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2010-03","conditions":["Non-functioning Pituitary Adenomas","Prolactinomas"],"enrollment":21,"completionDate":"2012-06"},{"nctId":"NCT02644304","phase":"PHASE2","title":"Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome","status":"UNKNOWN","sponsor":"Woman's Health University Hospital, Egypt","startDate":"2015-05","conditions":["Female Reproductive Problem"],"enrollment":88,"completionDate":"2016-12"},{"nctId":"NCT02134249","phase":"PHASE2,PHASE3","title":"Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome","status":"COMPLETED","sponsor":"Benha University","startDate":"2014-04","conditions":["Infertility"],"enrollment":200,"completionDate":"2015-10"},{"nctId":"NCT02461875","phase":"PHASE2","title":"Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome","status":"UNKNOWN","sponsor":"Aljazeera Hospital","startDate":"2013-05","conditions":["OHSS"],"enrollment":236,"completionDate":"2015-12"},{"nctId":"NCT01395602","phase":"PHASE1,PHASE2","title":"Effect of Cabergoline on Weight and Glucose Tolerance","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-04","conditions":["Body Weight","Impaired Glucose Tolerance in Obese"],"enrollment":40,"completionDate":"2011-07"},{"nctId":"NCT01009567","phase":"PHASE1,PHASE2","title":"Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2009-06","conditions":["Ovarian Hyperstimulation Syndrome"],"enrollment":10,"completionDate":"2013-07"},{"nctId":"NCT00242008","phase":"PHASE3","title":"A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-12","conditions":["Parkinson's Disease"],"enrollment":0,"completionDate":"2005-07"},{"nctId":"NCT01270711","phase":"","title":"Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-11","conditions":["Parkinson's Disease","Hyperprolactinemia"],"enrollment":22014,"completionDate":"2013-02"},{"nctId":"NCT00605683","phase":"PHASE3","title":"MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2007-11","conditions":["Idiopathic Parkinson's Disease"],"enrollment":679,"completionDate":"2012-03"},{"nctId":"NCT01957839","phase":"PHASE4","title":"Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients","status":"COMPLETED","sponsor":"Istanbul Bakirkoy Maternity and Children Diseases Hospital","startDate":"2010-03","conditions":["Adverse Reaction to Other Drugs and Medicines"],"enrollment":48,"completionDate":"2011-09"},{"nctId":"NCT00153972","phase":"PHASE4","title":"Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2005-02","conditions":["Parkinson's Disease"],"enrollment":39,"completionDate":"2009-01"},{"nctId":"NCT01651364","phase":"PHASE1","title":"A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2011-07","conditions":["Cocaine Dependence","Cocaine Abuse","Cocaine Addiction","Substance Abuse"],"enrollment":11,"completionDate":"2011-10"},{"nctId":"NCT01569256","phase":"NA","title":"Ovarian Hyperstimulation Syndrome and Cabergoline","status":"COMPLETED","sponsor":"Etlik Zubeyde Hanim Womens' Health and Teaching Hospital","startDate":"2008-03","conditions":["Polycystic Ovarian Syndrome","Ovarian Hyperstimulation Syndrome"],"enrollment":40,"completionDate":"2009-03"},{"nctId":"NCT01530490","phase":"EARLY_PHASE1","title":"Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention","status":"COMPLETED","sponsor":"Hospital de Cruces","startDate":"2007-08","conditions":["Complications Associated With Artificial Fertilization","Disorder of Endocrine Ovary"],"enrollment":80,"completionDate":"2010-09"},{"nctId":"NCT01459601","phase":"NA","title":"Cabergoline Effect on Blood Sugar in Type 2 Diabetics","status":"UNKNOWN","sponsor":"Mashhad University of Medical Sciences","startDate":"2012-01","conditions":["Diabetes Type 2"],"enrollment":10,"completionDate":"2012-02"},{"nctId":"NCT01065376","phase":"PHASE4","title":"The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation","status":"COMPLETED","sponsor":"Shin Kong Wu Ho-Su Memorial Hospital","startDate":"2010-01","conditions":["In Vitro Fertilization"],"enrollment":120,"completionDate":"2011-07"},{"nctId":"NCT00627003","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-11","conditions":["Restless Legs Syndrome"],"enrollment":43,"completionDate":"2003-05"},{"nctId":"NCT01052948","phase":"","title":"The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-01","conditions":["Parkinson's Disease","Hyperprolactinemia"],"enrollment":86939,"completionDate":"2009-12"},{"nctId":"NCT01143584","phase":"NA","title":"Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2010-05","conditions":["Macroprolactinoma"],"enrollment":20,"completionDate":"2012-03"},{"nctId":"NCT01014793","phase":"","title":"Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2005-05","conditions":["Acromegaly"],"enrollment":19,"completionDate":"2008-12"},{"nctId":"NCT00129181","phase":"NA","title":"Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Institute for Neurodegenerative Disorders","startDate":"2005-01","conditions":["Parkinson Disease","Parkinsonian Syndrome"],"enrollment":30,"completionDate":"2007-01"},{"nctId":"NCT00889525","phase":"PHASE3","title":"Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor","status":"COMPLETED","sponsor":"Seth Gordhandas Sunderdas Medical College","startDate":"2007-11","conditions":["Cushing's Disease","Corticotroph Adenoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT00625547","phase":"PHASE3","title":"A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-01","conditions":["Restless Legs Syndrome"],"enrollment":361,"completionDate":"2004-12"},{"nctId":"NCT00460616","phase":"","title":"Cardiac Valve Complications in Prolactinomas Treated With Cabergoline","status":"COMPLETED","sponsor":"Federico II University","startDate":"2007-01","conditions":["Prolactinomas"],"enrollment":50,"completionDate":"2007-09"},{"nctId":"NCT00653055","phase":"PHASE1","title":"Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2001-08","conditions":["To Determine Bioequivalence Under Fasting Conditions"],"enrollment":40,"completionDate":"2001-12"},{"nctId":"NCT00595140","phase":"PHASE4","title":"Acute Application of Pegvisomant and Octreotide in Acromegaly","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2008-01","conditions":["Acromegaly"],"enrollment":10,"completionDate":"2008-03"},{"nctId":"NCT00174239","phase":"PHASE4","title":"Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2004-07","conditions":["Parkinson Disease"],"enrollment":220,"completionDate":"2005-09"},{"nctId":"NCT00440258","phase":"PHASE3","title":"Cabergoline Reduces OHSS","status":"COMPLETED","sponsor":"Instituto Valenciano de Infertilidad, IVI VALENCIA","startDate":"2004-04","conditions":["Ovarian Hyperstimulation Syndrome"],"enrollment":60,"completionDate":"2006-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"Cabergoline"},{"form":"TABLET","route":"ORAL","productName":"Cabergoline"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148483","MMSL":"4317","NDDF":"005446","UNII":"LL60K9J05T","VUID":"4021014","CHEBI":"CHEBI:3286","VANDF":"4021014","INN_ID":"5860","RXNORM":"134895","UMLSCUI":"C0107994","chemblId":"CHEMBL1201087","ChEMBL_ID":"CHEMBL1201087","KEGG_DRUG":"D00987","DRUGBANK_ID":"DB00248","PUBCHEM_CID":"54746","SNOMEDCT_US":"109139002","IUPHAR_LIGAND_ID":"37","MESH_DESCRIPTOR_UI":"D000077465"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Pfizer","relationship":"Current Owner"},{"period":"1999","companyName":"Pfizer Japan Inc.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"FDA label","halfLife":"60 hours","bioavailability":"65%"},"publicationCount":2143,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"G02CB03","allCodes":["G02CB03","N04BC06"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jun","pmid":"41891968","title":"circOMA1 delivered by exosomes regulates DRD2‑mediated prolactinoma resistance.","journal":"International journal of molecular medicine"},{"date":"2026 Jan-Jun","pmid":"41884493","title":"Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities.","journal":"JFMS open reports"},{"date":"2026 Mar 25","pmid":"41879940","title":"Pregnancy and delivery after surgical remission in women with prolactinomas desiring pregnancy: Refining surgical indications.","journal":"Pituitary"},{"date":"2026 Dec","pmid":"41866242","title":"Aortic dissection during the perinatal period in women with Marfan-related disorders: a retrospective cohort study using the Japanese Diagnosis Procedure Combination database.","journal":"The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians"},{"date":"2026 Mar 8","pmid":"41827470","title":"Cabergoline Therapy and Tumor Growth Rate in Pituitary Microadenomas: A Retrospective Cohort Study.","journal":"Journal of clinical medicine"}],"companionDiagnostics":[],"genericManufacturers":9,"_genericFilersChecked":true,"genericManufacturerList":["Actavis Labs Fl Inc","Amneal","Apotex Corp","Impax Labs Inc","Ingenus Pharms Llc","Ivax Sub Teva Pharms","Pharmobedient","Somerset Theraps Llc","Strides Pharma Intl"],"status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1996","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-09-15T00:00:00.000Z","mah":"PFIZER","brand_name_local":null,"application_number":"NDA020664"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-03-12T00:00:00.000Z","mah":"IVAX SUB TEVA PHARMS","brand_name_local":null,"application_number":"ANDA077750"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-08-01T00:00:00.000Z","mah":"INGENUS PHARMS LLC","brand_name_local":null,"application_number":"ANDA204735"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-06-25T00:00:00.000Z","mah":"AMNEAL","brand_name_local":null,"application_number":"ANDA218618"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-09-09T00:00:00.000Z","mah":"SOMERSET THERAPS LLC","brand_name_local":null,"application_number":"ANDA218109"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":10,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:18:35.633677+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}